| Published Application/Species/Sample/Dilution | Reference |
|---|
- other; human; loading ...; fig 4c
| Ng P, Li J, Jeong K, Shao S, Chen H, Tsang Y, et al. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell. 2018;33:450-462.e10 pubmed publisher |
- reverse phase protein lysate microarray; human; loading ...; fig st6
| Cherniack A, Shen H, Walter V, Stewart C, Murray B, Bowlby R, et al. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell. 2017;31:411-423 pubmed publisher |
- reverse phase protein lysate microarray; human; loading ...; fig 3a
| . Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378-384 pubmed publisher |
- western blot; human; fig 8
| Heir P, Srikumar T, Bikopoulos G, Bunda S, Poon B, Lee J, et al. Oxygen-dependent Regulation of Erythropoietin Receptor Turnover and Signaling. J Biol Chem. 2016;291:7357-72 pubmed publisher |
- immunoprecipitation; human; fig 4
| Lee S, Frattini V, Bansal M, Castano A, Sherman D, Hutchinson K, et al. An ID2-dependent mechanism for VHL inactivation in cancer. Nature. 2016;529:172-7 pubmed publisher |
- immunohistochemistry; mouse; 1:100; fig 9a
| Mangiavini L, Merceron C, Araldi E, Khatri R, Gerard O Riley R, Wilson T, et al. Fibrosis and hypoxia-inducible factor-1α-dependent tumors of the soft tissue on loss of von Hippel-Lindau in mesenchymal progenitors. Am J Pathol. 2015;185:3090-101 pubmed publisher |
- western blot; mouse; 1:500; fig 5,6
| Hsiao H, Hsu T, Liu W, Hsieh W, Chou T, Wu Y, et al. Deltex1 antagonizes HIF-1α and sustains the stability of regulatory T cells in vivo. Nat Commun. 2015;6:6353 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:50
| Lessi F, Mazzanti C, Tomei S, Di Cristofano C, Minervini A, Menicagli M, et al. VHL and HIF-1?: gene variations and prognosis in early-stage clear cell renal cell carcinoma. Med Oncol. 2014;31:840 pubmed publisher |
| Hasegawa H, Kusumi Y, Asakawa T, Maeda M, Oinuma T, Furusaka T, et al. Expression of von Hippel-Lindau tumor suppressor protein (pVHL) characteristic of tongue cancer and proliferative lesions in tongue epithelium. BMC Cancer. 2017;17:381 pubmed publisher |
| Frost J, Galdeano C, Soares P, Gadd M, Grzes K, Ellis L, et al. Potent and selective chemical probe of hypoxic signalling downstream of HIF-? hydroxylation via VHL inhibition. Nat Commun. 2016;7:13312 pubmed publisher |
| Snell C, Turley H, McIntyre A, Li D, Masiero M, Schofield C, et al. Proline-hydroxylated hypoxia-inducible factor 1? (HIF-1?) upregulation in human tumours. PLoS ONE. 2014;9:e88955 pubmed publisher |
| Pascal L, Ai J, Rigatti L, Lipton A, Xiao W, Gnarra J, et al. EAF2 loss enhances angiogenic effects of Von Hippel-Lindau heterozygosity on the murine liver and prostate. Angiogenesis. 2011;14:331-43 pubmed publisher |
| Guo Y, Schoell M, Freeman R. The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIM(EL). Oncogene. 2009;28:1864-74 pubmed publisher |
| Bex C, Knauth K, Dambacher S, Buchberger A. A yeast two-hybrid system reconstituting substrate recognition of the von Hippel-Lindau tumor suppressor protein. Nucleic Acids Res. 2007;35:e142 pubmed |
| Meierhofer D, Mayr J, Fink K, Schmeller N, Kofler B, Sperl W. Mitochondrial DNA mutations in renal cell carcinomas revealed no general impact on energy metabolism. Br J Cancer. 2006;94:268-74 pubmed |
